These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19955104)

  • 21. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E; Wildemeersch P
    Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
    Andrade A; Wildemeersch D
    Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
    Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
    Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia.
    Shaw RW; Symonds IM; Tamizian O; Chaplain J; Mukhopadhyay S
    Aust N Z J Obstet Gynaecol; 2007 Aug; 47(4):335-40. PubMed ID: 17627692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
    Wildemeersch D; Rowe PJ
    Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection and performance of the levonorgestrel-releasing intrauterine system.
    Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
    Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hysteroscopic management of displaced levonorgestrel-releasing intrauterine system.
    Kuzel D; Hrazdirova L; Kubinova K; Dundr P; Cibula D; Mara M
    J Obstet Gynaecol Res; 2013 May; 39(5):1014-8. PubMed ID: 23496334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The levonorgestrel intrauterine system: the benefits of reduced bleeding.
    Cameron IT
    Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():27-32. PubMed ID: 11336431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
    Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
    Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders.
    Lukes AS; Reardon B; Arepally G
    Fertil Steril; 2008 Sep; 90(3):673-7. PubMed ID: 18001734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
    Römer T; Linsberger D
    Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
    Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
    Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
    Gemzell-Danielsson K; Schellschmidt I; Apter D
    Fertil Steril; 2012 Mar; 97(3):616-22.e1-3. PubMed ID: 22222193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.
    Kelekci S; Kelekci KH; Yilmaz B
    Contraception; 2012 Nov; 86(5):458-63. PubMed ID: 22832203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding pattern difference between levonorgestrel intrauterine system and copper intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women.
    Chen X; Li Q; Wang X; Chen J; Lv W; Shi B; Wang H; Luo J; Li J
    Curr Med Res Opin; 2018 May; 34(5):873-880. PubMed ID: 29298525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil.
    Bahamondes MV; de Lima Y; Teich V; Bahamondes L; Monteiro I
    Contraception; 2012 Sep; 86(3):244-50. PubMed ID: 22459236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
    Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
    Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.
    Sheng J; Zhang WY; Zhang JP; Lu D
    Contraception; 2009 Mar; 79(3):189-93. PubMed ID: 19185671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
    Labied S; Galant C; Nisolle M; Ravet S; Munaut C; Marbaix E; Foidart JM; Frankenne F
    Hum Reprod; 2009 Jan; 24(1):113-21. PubMed ID: 18812421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.